Pharma News

GLB-001 by GluBio Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Photo of MEEFRO MEEFRO Send an email December 21, 2023
0 0 Less than a minute

GLB-001 is under clinical development by GluBio Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.

Source link
#GLB001 #GluBio #Therapeutics #Refractory #Acute #Myeloid #Leukemia #Likelihood #Approval

Photo of MEEFRO MEEFRO Send an email December 21, 2023
0 0 Less than a minute
Photo of MEEFRO

MEEFRO

Related Articles

What is the current valuation of AstraZeneca’s Sabestomig

April 16, 2024

What is the current valuation of AbbVie’s ABBV-400

April 16, 2024

What is the current valuation of Merck’s MK-1084

April 16, 2024

What is the current valuation of AstraZeneca’s AZD-9574

April 16, 2024

Leave a Reply

Your email address will not be published. Required fields are marked *